Lipid CME
LECTURECME

Treating Diabetic Dyslipidemia: A Deep Dive into PCSK9 Inhibitors

Author(s)/Faculty: Yehuda Handelsman, MD, FACP, FNLA, MACE; Michael Miller, MD, FACC, FAHA; Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FASPC, FCCP, FACC
Release Date: 8/17/2018Expiration Date: 8/16/2019
Credit Type: CMENumber of Credits: 1
Content Type: LectureProvider:
Diabetes mellitus is associated with considerable increased risk of atherosclerotic cardiovascular disease. Lowering low-density lipoprotein cholesterol (LDL-C) plays an important role in therapeutic strategies designed to reduce cardiovascular risk. Nevertheless, 1 in 7 patients with diabetes, who are treated with statins, will experience a cardiovascular event within 5 years on treatment. Residual clinical risk has been demonstrated in statin trials, suggesting that additional therapy is required to achieve enhanced, effective prevention of cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated the ability to lower LDL-C, reduce LDL particle number, and decrease cardiovascular events. This educational activity will review the latest data regarding the management of dyslipidemia in patients with diabetes, as well as assess the newly released data regarding the safety, efficacy, and reduction of adverse cardiovascular outcomes with PCSK9 inhibitor therapy.